1034047-83-0

Upstream product

• 59649-56-8 2,3-diaminophenol 
• 1039715-27-9 7-hydroxy-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 
• 1039715-25-7 2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-7-ol 
• 1034046-82-6 6-{[4-(trifluoromethoxy)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-7-yl trifluoromethanesulfonate 
• 1034047-48-7 C₂₈H₁₈F₉N₃O₆S₂ 
• 627-31-6 1,3-Diiodopropane 
• 1034047-49-8 C₂₉H₂₀F₆N₄O₃S 
• 1034046-81-5 6-{[4-(Trifluoromethoxy)phenyl]-sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-7-ol 
• 100-39-0 benzyl bromide 
• 280566-45-2 2-chloro-6-(trifluoromethyl)pyridine-3-carboxylic acid 

Downstream Products

• 1039716-37-4 C₂₅H₂₁F₆N₅O₄S 
• 1034046-77-9 C₂₉H₂₅F₆N₅O₅S 
• 1039716-35-2 C₂₅H₁₈F₆N₄O₃S 
• 1375077-55-6 C₂₅H₁₉F₆N₃O₄S 
• 1034046-77-9 C₂₉H₂₅F₆N₅O₅S 

Relevant academic research and scientific papers

The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization

Bombesin receptor subtype 3 (BRS-3) is an orphan G-protein coupled receptor expressed primarily in the hypothalamus which plays a role in the onset of both diabetes and obesity. We report herein our progress made towards identifying a potent, selective bo